Aliskiren: An orally active renin inhibitor

Journal of Pharmacy and Bioallied Sciences

Volumn 3, Issue 2, 2011, Pages 189-193

  Wal, Pranay ^a   Wal, Ankita ^a   Rai, Awani ^a   Dixit, Anuj ^a  

^a PRANVEER SINGH INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Aliskiren; hypertension; mechanism of action; renin inhibitors; renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HEMOGLOBIN; HYDROCHLOROTHIAZIDE; ITRACONAZOLE; KETOCONAZOLE; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACEBO; POTASSIUM; URIC ACID; VALSARTAN; VERAPAMIL;

ALBUMINURIA; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL SYMPTOM; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYDROPHILICITY; HYPERKALEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 79957564047     PISSN: None     EISSN: 09757406     Source Type: Journal    
DOI: 10.4103/0975-7406.80764     Document Type: Review

References (46)

1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [US Dept of Health and Human Services Web site]. Available from: http://www.nhlbi.nih.gov/ guidelines/ hypertension/jnc7full.pdf. [Last accessed on 2010 Jul 02].
2. Top 300 Prescriptions for 2005 [RxList.com Web site]. Available from: http://www.rxlist.com/script/main/art.asp?articlekey=79509. [Last accessed on 2010 Jul 02].
3. Linn WD. Angiotensin-converting enzyme inhibitors in left ventricular dysfunction. Pharmacotherapy 1996;16:50S-8.
4. Maggioni AP. Efficacy of angiotensin receptor blockers in cardiovascular disease. Cardiovasc Drugs Ther 2006;20:295-308. (Pubitemid 44710747)
5. Hilleman DE, Lucas BD Jr. Angiotensin-converting enzyme inhibitors and stroke risk: Benefit beyond blood pressure reduction? Pharmacotherapy 2004;24:1064-76.
6. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. BMJ 2004;329:828.
7. Greenberg B, Zannad F, Pitt B. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction. Am J Cardiol 2006;97:34F-40.
8. Yokokawa F, Maibaum J. Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: New patent applications in years 2000-2008. Expert Opin Ther Patents 2008;18:581-602.
9. Vaidyanathan S, Limoges D, Yeh CM, Dieterich HA. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers, Clin Pharmacol Ther 2006;79:64 .
10. Vaidyanathan S, Zhao C, Yeh CM, Dieterich HA. Pharmacokinetics and safety of the novel oral renin inhibitor aliskiren in patients with type 2 diabetes. Clin Pharmacol Ther 2006;79:12.
11. Meredith PA. Organ protection and optimal blood pressure control. Am J Hypertens 1995;8:59S-62.
12. Myers MG. Twenty-four-hour blood pressure control: A brief review of aspects of target-organ protection, J Hypertens Suppl 1996;14:S7-10.
13. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. J Hypertens 1993;11:1133-7. (Pubitemid 23307888)
14. Jandeleit-Dahm K, Cooper ME. Hypertension and diabetes: Role of the renin-angiotensin system. Endocrinol Metab Clin North Am 2006;35:469-90, (Pubitemid 44321946)
15. Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001;37:1047-52. (Pubitemid 32304002)
16. Kostis JB. Angiotensin converting enzyme inhibitors. I. Pharmacology. Am Heart J 1988;116:1580-91.
17. Mimran A, Ribstein J. Angiotensin receptor blockers: Pharmacology and clinical significance. J Am Soc Nephrol 1999;10:S273-7.
18. Brown NJ. Eplerenone: Cardiovascular protection. Circulation 2003;107:2512-8. (Pubitemid 36605237)
19. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II- forming enzyme in the human heart. J Biol Chem 1990;265:22348-57. (Pubitemid 120014308)
20. Okunishi H, Miyazaki M, Toda N. Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 1984;2:277-84. (Pubitemid 14077405)
21. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92. (Pubitemid 28429123)
22. Saris JJ, van Dijk MA, Kroon I, Schalekamp MA, Danser AH. Functional importance of angiotensin-converting enzyme-dependent in situ angiotensin II generation in the human forearm. Hypertension 2000;35:764-8. (Pubitemid 30165323)
23. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46. (Pubitemid 351793017)
24. Azizi M, Ménard J, Bissery A, Guyenne TT, Bura-Rivière A, Vaidyanathan S, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-rennin feedback interruption. J Am Soc Nephrol 2004;15:3126-33. (Pubitemid 39578845)
25. Buczko W, Hermanowicz JM. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep 2008;60:623-31.
26. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): Comparison with enalapril. Hypertension 2002;39:E1-8.
27. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368:1449-56. (Pubitemid 44573444)
28. Pool JL. Direct renin inhibition: Focus on aliskiren. J Manag Care Pharm 2007;13:21-33.
29. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren: A novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698-705. (Pubitemid 36976519)
30. Judy WM, Cheng BS. Aliskiren: Renin inhibitor for hypertension management. Clinical Therapeutics 2008;30:31-47
31. Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007;35:1418-28. (Pubitemid 47121784)
32. Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Armin Dieterich H. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006;45:1125-34. (Pubitemid 44631391)
33. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-8. (Pubitemid 40354519)
34. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren: A novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005;23:417-26. (Pubitemid 40279646)
35. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137-43. (Pubitemid 37549068)
36. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL, et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006;29:997-1005. (Pubitemid 46206586)
37. O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007;49:276-84. (Pubitemid 46143002)
38. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-26. (Pubitemid 44885684)
39. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, et al. Aliskiren, an orally effective rennin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20:11-20. (Pubitemid 46014059)
40. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-63. (Pubitemid 46400330)
41. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49:1047-55. (Pubitemid 351664315)
42. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet 2007;370:221-9. (Pubitemid 47069535)
43. Tekturna (aliskiren) tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2007. http://www.pharma.us. novartis.com/ product/pi/pdf/tekturna.pdf. Accessed April 16, 2007.
44. Cada DJ, Levien T, Baker DE. Aliskiren. Hosp Pharmacy 2007;42:737-49.
45. Vaidyanathan S, Bigler H, Yeh C, Bizot MN, Dieterich HA, Howard D, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007;46:661-75. (Pubitemid 47204852)
46. Aliskiren Clinical Trials. Available from: http://www.clinicaltrials.gov/ ct/action/GetStudy. [Last accessed on 2007 Sep 26].